Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bioinfra Co., Ltd. (199730:KRX), powered by AI.
Bioinfra Co., Ltd. is currently trading at ₩3,180. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bioinfra Co., Ltd. on Alpha Lenz.
Bioinfra Co., Ltd.'s P/E ratio is -1.7.
“Bioinfra Co., Ltd. trades at a P/E of -1.7 (undervalued) with modest ROE of -41.4%.”
Ask for details →Bioinfra Co., Ltd. is a biotechnology company specializing in the development and commercialization of innovative medical devices and diagnostic products. The primary function of the company is to enhance healthcare outcomes by providing cutting-edge solutions that improve the accuracy and efficiency of diagnostics. Bioinfra's product portfolio includes advanced testing kits and devices that cater to various medical fields, such as oncology, infectious diseases, and personalized medicine. By focusing on research and development, Bioinfra Co., Ltd. impacts the biotechnology sector significantly, contributing to advancements in early detection and treatment methodologies. The company's role in the financial market is tied to the growing demand for reliable and efficient diagnostic tools, especially as global health challenges become more complex and prevalent. With its commitment to innovation and quality, Bioinfra Co., Ltd. aligns itself with the needs of healthcare providers, laboratories, and research institutions, facilitating improvements in patient care and medical research efficiency. Its operations underscore a vital segment of the market that continues to expand as the need for advanced healthcare solutions rises globally.
“Bioinfra Co., Ltd. trades at a P/E of -1.7 (undervalued) with modest ROE of -41.4%.”
Ask for details →Bioinfra Co., Ltd. (ticker: 199730) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $15.5B.
The current price is ₩3,180 with a P/E ratio of -1.69x and P/B of 0.94x.
ROE is -41.45% and operating margin is -27.08%. Annual revenue is $23.1B.